Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-Candida IgY
- Development stage
- Preclinical
- Lead developer
- Immunology Research Institute in Gifu
- Modality
- Antibody-Based Therapeutics
- Administration
- Topical
01
Overview
Anti-Candida IgY is a biologic antibody therapy being developed by the Immunology Research Institute in Gifu (IRIG) for the prevention and treatment of candidiasis. The product consists of immunoglobulin Y (IgY) antibodies extracted from the yolks of eggs laid by chickens immunized with *Candida albicans* antigens. Its mechanism of action involves specifically binding to *C. albicans* to block its adherence to host cells, thereby interfering with fungal colonization, growth, and virulence. Research has demonstrated that this antibody significantly reduces the adherence capacity of the fungus to human cells in a dose-dependent manner. It is primarily being investigated for the management of mucosal and cutaneous infections and is currently in the preclinical research stage.
- Other names
- anti-CA IgYCandida albicans IgY antibodychicken egg yolk antibody against Candida albicans
02
Targets
Als3 (Agglutinin-like sequence protein 3)
Beyond the preview
Go deeper on anti-Candida IgY.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-Candida IgY.